PIA
ATRA icon

Piedmont Investment Advisors’s Atara Biotherapeutics ATRA Stock Holding History

Piedmont Investment Advisors’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-28
Closed -$26K – 1133
2018
Q2 		$26K Buy
+28
New +$30.1K ﹤0.01% 1503

Other funds holding ATRA

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Piedmont Investment Advisors's ATRA Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Atara Biotherapeutics (ATRA) in Q3 2018, closing a stake of 28 shares — an estimated $26K sold.

Piedmont Investment Advisors first reported a position in ATRA in Q2 2018 and held it in 1 quarter. The position peaked at $26K in Q2 2018. 115 funds tracked by Wall St. Rank hold ATRA as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Atara Biotherapeutics position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 28 Atara Biotherapeutics shares in Q3 2018, an estimated $26K.
  • Piedmont Investment Advisors first reported a position in Atara Biotherapeutics in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Atara Biotherapeutics position peaked at $26K in Q2 2018.
  • 115 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.